Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease.
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes complicated by non-alcoholic fatty liver disease
- Registration Number
- JPRN-UMIN000018166
- Lead Sponsor
- Toranomon Hospital, Department of Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Contraindication for SGLT2 inhibitor. Ineligible patients by judgement of family doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Histologial changes of liver and safety of treament are evaluated at two points of the baseline and 24 weeks after the start of treatment.
- Secondary Outcome Measures
Name Time Method Fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, and body composition are evaluated at two points of the baseline and 24 weeks after the start of treatment.